Vertex Pharmaceuticals Incorporated
VRTX
$489.10
$3.210.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.76% | 0.98% | -492.44% | 57.13% | 18.31% |
| Total Depreciation and Amortization | -54.87% | 26.37% | 30.43% | 37.89% | 22.92% |
| Total Amortization of Deferred Charges | 113.56% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 305.47% | 5,314.29% | 140.23% | 8.04% | -85.35% |
| Change in Net Operating Assets | 33.22% | -16.62% | -198.37% | -6.91% | -822.88% |
| Cash from Operations | 149.19% | 7.99% | -430.89% | 45.19% | -78.25% |
| Capital Expenditure | -59.38% | -66.75% | -15.77% | -62.47% | -72.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.96% | -263.55% | -61.56% | -15.43% | -495.98% |
| Cash from Investing | 7.29% | -195.67% | -52.58% | -16.51% | -604.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 89.17% | 52.21% | -24.55% | -24.53% | -15.38% |
| Issuance of Common Stock | -26.08% | -45.45% | -6.14% | 19.01% | -10.08% |
| Repurchase of Common Stock | -178.45% | -129.96% | -1,176.43% | -21.81% | -7,171.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 160.00% | -18.18% | -18.18% | 218.18% | 37.50% |
| Cash from Financing | -226.63% | -134.85% | -2,172.83% | -21.31% | -398.01% |
| Foreign Exchange rate Adjustments | -272.63% | 201.33% | -125.00% | -230.00% | -32.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.19% | -31.78% | -633.74% | 1.11% | -155.75% |